[go: up one dir, main page]

WO1997044059A3 - Cartilage type ii collagen as an angiogenic factor - Google Patents

Cartilage type ii collagen as an angiogenic factor Download PDF

Info

Publication number
WO1997044059A3
WO1997044059A3 PCT/US1997/009861 US9709861W WO9744059A3 WO 1997044059 A3 WO1997044059 A3 WO 1997044059A3 US 9709861 W US9709861 W US 9709861W WO 9744059 A3 WO9744059 A3 WO 9744059A3
Authority
WO
WIPO (PCT)
Prior art keywords
collagen
angiogenesis
angiogenic factor
cartilage type
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1997/009861
Other languages
French (fr)
Other versions
WO1997044059A2 (en
Inventor
A Robin Poole
Anne Marriott
Mauro Alini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shriners Hospitals for Children
Original Assignee
Shriners Hospitals for Children
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shriners Hospitals for Children filed Critical Shriners Hospitals for Children
Priority to AU33045/97A priority Critical patent/AU3304597A/en
Publication of WO1997044059A2 publication Critical patent/WO1997044059A2/en
Publication of WO1997044059A3 publication Critical patent/WO1997044059A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The subject invention concerns materials and methods for inhibiting or promoting angiogenesis. It has been determined that cartilage type II collagen is an angiogenesis promoter. The subject invention provides methods for reducing unwanted angiogenesis as well as methods for promoting appropriate angiogenesis, for example, in wound repair.
PCT/US1997/009861 1996-05-23 1997-05-23 Cartilage type ii collagen as an angiogenic factor Ceased WO1997044059A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33045/97A AU3304597A (en) 1996-05-23 1997-05-23 Cartilage type ii collagen as an angiogenic factor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1815996P 1996-05-23 1996-05-23
US60/018,159 1996-05-23

Publications (2)

Publication Number Publication Date
WO1997044059A2 WO1997044059A2 (en) 1997-11-27
WO1997044059A3 true WO1997044059A3 (en) 1997-12-24

Family

ID=21786559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/009861 Ceased WO1997044059A2 (en) 1996-05-23 1997-05-23 Cartilage type ii collagen as an angiogenic factor

Country Status (2)

Country Link
AU (1) AU3304597A (en)
WO (1) WO1997044059A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122635B2 (en) 1999-01-06 2006-10-17 University Of Southern California Method and composition for angiogenesis inhibition
DE60042487D1 (en) 1999-07-13 2009-08-13 Univ Southern California METHOD AND COMPOSITION FOR ANGIOGENESIS INHIBITION WITH ANTAGONISTS AGAINST MMP-9 AND BETA1 INTEGRINS
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
JP2007191467A (en) * 2005-12-20 2007-08-02 Pentax Corp A new cell function regulator produced by chondrocytes with hypertrophicity

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007520A1 (en) * 1992-09-25 1994-04-14 Autoimmune, Inc. Method of treating rheumatoid arthritis with type ii collagen
WO1994018563A1 (en) * 1993-02-12 1994-08-18 Rhode Island Hospital Detection of type ii collagen and its peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994007520A1 (en) * 1992-09-25 1994-04-14 Autoimmune, Inc. Method of treating rheumatoid arthritis with type ii collagen
WO1994018563A1 (en) * 1993-02-12 1994-08-18 Rhode Island Hospital Detection of type ii collagen and its peptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALINI M. ET AL: "A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone formation", DEVELOPMENTAL BIOLOGY, vol. 176, no. 1, 1996 - 1996, pages 124 - 132, XP002044392 *
HOLLANDER, A.P. ET AL: "Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 93, no. 4, 1994, pages 1722 - 1732, XP002044391 *
OLIVER S.J. ET AL: "Suppression of collagen-induced Arthritis using an angiogenesis inhibitor, AGM-1470 and a microtubule stabilizer, Taxol", CELLULAR IMMUNOLOGY, vol. 157, 1994, pages 291 - 299, XP002044393 *
POSTLETHWAITE A. ET AL: "Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 75, no. 2, 1978, WASHINGTON US, pages 871 - 875, XP002044394 *

Also Published As

Publication number Publication date
AU3304597A (en) 1997-12-09
WO1997044059A2 (en) 1997-11-27

Similar Documents

Publication Publication Date Title
AU1527897A (en) Method for treating the prostate
ZA976696B (en) Treated titanium dioxide.
WO1996017072A3 (en) Recombinant alphavirus vectors
ZA978178B (en) Composition.
ZA974772B (en) Surfboard or sailboard and method for the manufacture thereof.
AU4565197A (en) Colostrinin, and uses thereof
ZA973193B (en) Beverage stabilization.
ZA975055B (en) Point blades.
ZA9711360B (en) Waterborne coating compositions having ultra low formaldehyde concentration.
ZA975261B (en) Composition.
ZA973707B (en) Method for treating inflammation.
ZA9710542B (en) Modified 1,3-propanediol-based polyesters.
AU7874698A (en) Luminescent tool, its auxiliary member and method of preserving biotool and the auxiliary member
ZA976935B (en) Stable web having enhanced extensibility and method for making same.
GB2319912B (en) Oscillator and method for controlling the same
MX243702B (en) Method for modified aminoplast compounds aminoplast compounds obtained thereby and coatings containing the same.
AU4803999A (en) Salt-stable modified starch
WO1997044059A3 (en) Cartilage type ii collagen as an angiogenic factor
AU4853297A (en) Container formed from copolyester composition, copolyester composition therefor and method of producing the same
ZA979131B (en) Polyol combination.
ZA97942B (en) E1 compression control method.
ZA972061B (en) New method.
ZA978669B (en) Refrigerant disposal.
GB2331524A (en) Polyester compositions
ZA977036B (en) Substituted oxadiazine derivatives.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GE HU IL IS JP KP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK TR TT UA UG UZ VN YU AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: CA

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 97543083

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase